Mechanisms of hypercoagulation in malignancy and during chemotherapy

Haemostasis

Volumn 28, Issue SUPPL. 3, 1998, Pages 50-60

  Falanga, Anna ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Chemotherapy; Haemostasis; Hypercoagulation; Malignancy; Thrombosis

Indexed keywords

CANCER CHEMOTHERAPY; CANCER PATIENT; CONFERENCE PAPER; DRUG CHOICE; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; TREATMENT PLANNING;

EID: 0032458322     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022405     Document Type: Conference Paper

References (59)

1. Rickles FR, Edwards RL: Activation of blood coagulation in cancer Trousseau's syndrome revisited. Blood 1983;62:14-31.
2. Donati MB: Cancer and thrombosis from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278-281.
3. Barbui T, Finazzi G, Falanga A: The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-3102.
4. Salzman EW, Hirsh J: Prevention of venous thromboembolism: in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Haemostasis and Thrombosis. Basic principles and clinical practice. Philadelphia, Lippincott, 1987, pp 1252-1265.
5. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D'Angelo A, Barbui T: Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993;85:745-750.
6. Barbui T, Finazzi G, Donati MB, Falanga A: Antiblastic therapy and thrombosis; in GG Neri Serneri, R Abbate, G Gensini, D Frisco (eds): Thrombosis an update. Florence, Scientific Press, 1992, pp 305-314.
7. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MB, Hryniuk W, DePauw S: The thrombogenic effect of anticancer drug therapy in women with Stage II Breast Cancer. New Engl J Med 1998;318:404-407.
8. Levine MM, Hirsh J, Gent M, Arnold A, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P: Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889.
9. Rickles FR, Levine MN, Edwards RL: Hemostatic alterations in cancer patients. Cancer Met Rev 1992;11:237-248.
10. Falanga A, Barbui T, Rickles FR, Levine MN: Guidelines for clotting studies in cancer patients. Thromb Haemost 1993;70:343-50.
11. Falanga A, Ofosu FA, Delaini F, Oldani E, Dewar L, Lui L, Barbui T: The hypercoagulable state in cancer evidence for impaired thrombin inhibition. Blood Coag Fibrin 1994;5(suppl):19-223.
12. Poggi A, Donati MB and Garattini S: Fibrin and cancer cell growth: Problems in the evaluation of experimental models: in Donati MB, Davison JF and Garattini S (eds): Malignancy and the Hemostatic System. Raven Press, 1981, pp 89-101.
13. Bani MR, Falanga A, Alessio MG, Radice E, Consonni R, Giavazzi R, Donati MB: Blood coagulation changes in nude mice bearing human colon carcinomas. Int J Cancer 1992;50:75-79.
14. Donati MB, Poggi A, Semeraro N: Coagulation and malignancy; in Poller L (ed): Recent Advances in Blood Coagulation. Churchill Livingstone, 1981, p.227-259.
15. Falanga A, Iacoviello L, Evangelista V, Consonni R, Belotti D, D'Orazio A, Donati MB, Barbui T: Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood 1995;86:1072-1081.
16. Lindhal AK, Sandset PM, Abilgaard U: Indices of hypercoagulation in cancer as compared with those with acute inflammation and acute infarction. Haemostasis 1990;20:253-262.
17. Seitz R, Rappe N, Kraus M, Immel A, Wolf M, Maasberg M, Edbring R, Pfab R, Havemann K: Activation of coagulation and fibrinolysis in patients with lung cancer relation to tumour stage and prognosis. Blood Coag Fibrin 1993;4:249-254.
18. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RCN: Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346:1004-1005.
19. Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, Julian JA, Barbui T: The effect of very low dose warfarin on markers of hypercoagulation in metastatic breast cancer. Results from a randomized trial. Thromb Haemost 1998;79:23-27.
20. Rocha E, Pàramo JA, Fernàdez FJ, Cuesta B, Hernandez M, Paloma MJ, Rifòn J: Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 189;54:699-707.
21. Gadduci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V: Pretreatment plasma levels of fibrinopeptide A (FPA), D-Dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynec Oncol 1994;53:352-356.
22. Licciarello JTW, Moake JL, Rudi CK, Karp DD, Hong WK: Elevated plasma von Willebrand Factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300.
23. Bazarbachi A, Scrobohachi ML, Gisselbracht C, Marolleau JP, Mansi A, Brice P, Gorra P, Drouet L: Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation possible implications in the pathogenesis of veno-occlusive disease. Nouv Revue fr Hémat 1993;35:135-140.
24. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, Bandini G, Cirio TM, Tura S: Endothelium and bone marrow transplantation. Bone Marrow Transpl 1996;17:277-280.
25. Semeraro N, Montemurro P, Conese M, Giordano D, Stella M, Restaino A, Cagnazzo G, Colucci M: Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynaecological malignancies. Int J Cancer 1990;45:251-254.
26. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W: Circulating activated platelets in myeloproliferate disorders. Thromb Res 1991;61:271-278.
27. Andoh D, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T: Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 1987;59:748-754.
28. Nemerson Y: The tissue factor pathway of blood coagulation. Sem Hematol 1992;29:170-176.
29. Falanga A, Gordon SG: Isolation and characterization of cancer procoagulant; A Cysteine proteinase from malignant tissue. Biochemistry 1985;245:5558-5561.
30. Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG: Cancer procoagulant in human tumour cells: Evidence from melanoma patients. Cancer Res 1986;46:6471-6474.
31. Gordon SG, Hashiba U, Poole MA, Cross BA, Falanga A: Cysteine proteinase procoagulant from amnionchorion. Blood 1985;66:1261-1265.
32. Van de Water L, Tracy PB, Aronson D, Mann KG, Dvorak HF: Tumour cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985;45:5521-5525.
33. Edwards RL, Silver J, Rickles FR: Human tumour procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost 1993;63:205-213.
34. Gordon SG: Tumour cell procoagulants and their role in malignant disease. Sem Thromb Haemost 1992;18:424-433.
35. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Gambacorti Passerini C, Gordon SG, Barbui T: Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia cells. Blood 1998;92:143-151.
36. Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost 1997;78:759-764.
37. Donati MB, Falanga A, Consonni R, Alessio MG, Bassan R, Buelli M, Bolrin L, Catani L, Pogliani E, Gugliotta L, Masera G, Barbui T: Cancer procoagulant in acute non lymphoid leukemia relationship of enzyme detection to disease activity. Thromb Haemost 1990;64:11-16.
38. Kwaan HC, Keet HN: Fibrinolysis and cancer. Semin Thromb Haemost 1990;16:230-235.
39. Stephens R, Alitalo R, Tapiovaara H, Vaheri A: Production of an active urokinase by leukemia cells. A novel distinction from cell lines of solid tumours. Leuk Res 1988;12:419-422.
40. Hajjar KA: Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995;74:294-301.
41. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr: Recombinant tumour necrosis factor induces procoagulant activity in cultured human vascular endothelium. Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537.
42. Moore KL, Esmon ML: Tumour necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-165.
43. Falanga A, Marchetti M, Giovanelli S, Barbui T: All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 1996;87:613-617.
44. Van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W: Progress of fibrinolysis during tumour necrosis factor infusion in humans. Concomitant increase of tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990;76:2284-2289.
45. Honn KV, Tang DG, Chen YQ: Adhesion molecules and site-specific metastases; in Neri Serneri GG, Abbate R, Gensini G, Prisco D (eds): Thrombosis an Update. Florence, Scientific Press, 1992, pp 269-303.
46. Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T: All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukemia cell line NB4. Br J Haematol 1996;93:360-366.
47. Giavazzi R, Foppolo M, Dossi R, Remuzzi A: Rolling and adhesion of human tumour cells on vascular endothelium under physiological flow conditions. J Clin Invest 1993;92:3038-3044.
48. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215.
49. Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, Mantovani A, Donati MB: Generation of procoagulant activity by mononuclear phagocytes A possible mechanism contributing to blood clotting activation within malignant tissue. Blood 1983;62:2721-2723.
50. Poggi A, Rossi C, Beviglia L, Calabrese R, Donati MB: Platelets-tumour cell interactions; in Joseph M (ed): The handbook of immunopharmacology. London, Academic Press, 1995, pp 151-165.
51. Al-Mondhiry H: Betathromboglobulin and platelet factor 4 in patients with cancer. Correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983;14:105-111.
52. Gasic GJ, Gasic TB: Plasma membrane vesicles as mediators of interactions between tumour cells and components of the haemostatic and immune system; in Jamieson GA (ed): Interactions of platelets and tumour cells. New York, Liss, 1982, pp 429.
53. Grignani G, Jamieson GA: Platelets in tumour metastasis generation of ADP by tumour cells is specific but not unrelated to metastatic potential. Blood 1988;71:844-849.
54. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR: Chemotherapy enhances endothelial cell reactivity to platelets. Clin Expl Metastasis 1990;8;511-518.
55. Nicolson GL, Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumour cell - endothelial cell interactions as a model for assessing vascular endothelial intergrity. Cancer Res 1985;45:331-336.
56. Sporn LA, Rubin P, Marder VJ, Wagner DD: Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood 1984;64:567-570.
57. Poggi A, Kornblitt L, Delaini F, Colombo T, Mussoni L, Reyers I, Donati MB: Delayed hypercoagulability after a single dose of adriamycin to normal rats. Thromb Res 1979;16:639-650.
58. Walsh J, Wheeler HR, Geczy CL: Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992;81:480-488.
59. Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE: Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transpl 1990;5:39-42.